PRNewsWire
30 May 2026, 03:32 UTC · 3h ago
Source · https://www.prnewswire.com/news-releases/the-results-of-phase-iii-optitrop-lung05-study-of-sacituzumab-tirumotecan-sac-tmt-presented-as-an-asco-oral-presentation-and-simultaneously-published-in-the-lancet-302786204.html
Read source
Search tags
Story key points
3 claims · impact-rated
The Phase III OptiTROP-Lung05 study demonstrated that sacituzumab tirumotecan (sac-TMT) plus pembrolizumab significantly prolonged progression-free survival (PFS) compared to pembrolizumab alone in first-line NSCLC. — Meeting a primary endpoint of PFS in a Phase III trial for first-line lung cancer is a major catalyst for drug approval and future commercial revenue.
+0.80The combination therapy showed a positive trend in overall survival (OS) and consistent PFS benefits across all prespecified subgroups. — Positive OS trends reinforce the efficacy profile and increase the likelihood of a broad label indication.
+0.50The combination group experienced a higher incidence of grade ≥3 treatment-emergent adverse events, primarily driven by hematologic events from sac-TMT. — Increased toxicity in combination therapies can complicate the safety profile and potentially limit the target patient population.
-0.20Ticker attribution
Continue reading
6 related stories
Model heads
The company's Phase III clinical study for sac-TMT showed significant prolongation of PFS and positive trends in OS, with results published in The Lancet.
The study demonstrates that pembrolizumab (Keytruda) performs effectively as part of a synergistic combination therapy for NSCLC.
Impact vectors
7 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Business Wire
10h ago
